Cingulate (CING) to Release Quarterly Earnings on Monday

Cingulate (NASDAQ:CING) is projected to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($1.48) per share for the quarter.

Cingulate Stock Down 3.2 %

Shares of NASDAQ CING opened at $3.96 on Friday. Cingulate has a fifty-two week low of $1.80 and a fifty-two week high of $20.83. The business has a fifty day moving average price of $4.34 and a two-hundred day moving average price of $4.53.

Analyst Ratings Changes

CING has been the subject of several recent analyst reports. Roth Mkm initiated coverage on shares of Cingulate in a research report on Friday, January 10th. They set a “buy” rating and a $12.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Cingulate in a research note on Thursday, March 6th. Finally, Roth Capital upgraded Cingulate to a “strong-buy” rating in a research report on Friday, January 10th.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.